医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ACM Global Central Laboratory Officially Opens New Shanghai Lab Facility

2014年09月10日 AM02:11
このエントリーをはてなブックマークに追加


 

ROCHESTER, N.Y.

ACM Global Central Laboratory, a diagnostic central laboratory delivering high-quality testing services that optimize clinical trial outcomes, today announced the official opening of its recently acquired Shanghai lab facility. ACM Shanghai is an element of ACM Global’s acquisition of Phoenix Pharma Central Services Pte. Ltd (Phoenix PCS), a premier central laboratory services provider for Asia-Pacific clinical trials. Leveraging existing staff and local knowledge from Phoenix PCS, the fully-operational lab enables ACM Global to provide support of clinical trials throughout Shanghai and beyond with increased speed and efficiency.

“The opening of our wholly-owned Shanghai lab facility follows the successful launch of ACM Singapore in June, further extending ACM Global’s network of operating labs in an increasingly important region for clinical research,” said Jerry Boxall, managing director, ACM Europe and Asia. “We are thrilled to operate the new Shanghai and Singapore facilities in parallel to our locations in the United States, United Kingdom and India, providing the same robust capabilities and standards in scientific expertise. By seamlessly integrating operations of both new and existing facilities, we’ve established a network of harmonized laboratories producing a single database of test data for all global projects.”

ACM Shanghai is 10,000 square feet in size and located within the Shanghai International Medical Zone of the city’s Pudong district. The purpose-designed lab facility houses cutting-edge instruments and equipment identical to ACM’s US and UK laboratories and provides a broad menu of safety and specialty testing, including chemistry, hematology, urinalysis, and immunology testing. Lee Chiew Yan, PhD, FRCPath, who joined ACM Global from Phoenix PCS as Director, Singapore and China Operations, oversees both the ACM Shanghai and Singapore facilities, including all staff and operations. She brings more than 20 years of experience in central laboratory operations within the Asia-Pacific region.

The addition of ACM owned and operated laboratories in Shanghai and Singapore is the latest in a series of growth-driven investments made by ACM Global, which in 2013 moved its European laboratory operations into a new, purpose-built, and expanded facility in York, England. Since 1994, ACM Global has provided central laboratory testing services to more than 2,300 clinical studies, involving more than 7,000 investigator sites in 60 countries, giving the company a broad range of global experience and an in-depth understanding of regional requirements. To learn more information about ACM Global’s central lab services and experience in the region, please call 1-866-405-0400 or visit www.acmgloballab.com/asiapac.

About ACM Global Central Laboratory

ACM Global Central Laboratory specializes in delivering high quality central laboratory testing services designed to optimize clinical trial outcomes. Through a powerful combination of robust global capabilities, operational and scientific expertise and unsurpassed service, ACM Global acts as an extension of our clients’ clinical teams to develop and execute Smarter Testing strategies that deliver reliable outcomes for their clinical development programs. Operating in more than 60 countries, ACM Global’s analytical team performs more than 15 million diagnostic tests each year from a test menu with more than 1,500 tests spanning all medical disciplines, including pathology, microbiology and molecular diagnostics, flow cytometry, specialized biomarkers, and pharmacogenomics.

For more information, visit www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400.

CONTACT

For ACM Global Central Laboratory
Kelly Foster, +1 619-224-1261
kelly@johnkellyfoster.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表